The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InAlumis Inc. (ALMS) received a stock rating upgrade to 'Buy' following the release of strong Phase 3 clinical trial data for its psoriasis treatment, envudeucitinib. The drug demonstrated a 74% efficacy rate on the PASI 75 scale, placing it in direct competition with Johnson & Johnson’s recently approved Icotyde. Analysts highlighted the drug's potential to capture significant market share in the oral psoriasis medication space due to its competitive clinical profile. The company has outlined a regulatory roadmap, targeting a New Drug Application (NDA) submission in the second half of 2026. While the long-term timeline for commercialization remains a factor, the clinical success significantly de-risks the company's primary asset. Market participants are also looking forward to additional data readouts expected in 2026 for other potential indications of the drug.